CN113508841A - 一种营养丰富的早茶 - Google Patents
一种营养丰富的早茶 Download PDFInfo
- Publication number
- CN113508841A CN113508841A CN202110780131.6A CN202110780131A CN113508841A CN 113508841 A CN113508841 A CN 113508841A CN 202110780131 A CN202110780131 A CN 202110780131A CN 113508841 A CN113508841 A CN 113508841A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- inulin
- dha
- blood
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008935 nutritious Nutrition 0.000 title claims abstract description 13
- 241001122767 Theaceae Species 0.000 title description 20
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 39
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 39
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 32
- 229920001202 Inulin Polymers 0.000 claims abstract description 29
- 229940029339 inulin Drugs 0.000 claims abstract description 29
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 21
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 21
- 235000013976 turmeric Nutrition 0.000 claims abstract description 21
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 20
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 17
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 17
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 17
- 229940016667 resveratrol Drugs 0.000 claims abstract description 17
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 15
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 15
- 239000011710 vitamin D Substances 0.000 claims abstract description 15
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 15
- 229940046008 vitamin d Drugs 0.000 claims abstract description 15
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 14
- 229940046009 vitamin E Drugs 0.000 claims abstract description 14
- 239000011709 vitamin E Substances 0.000 claims abstract description 14
- 229940045997 vitamin a Drugs 0.000 claims abstract description 14
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 13
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 13
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 13
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 12
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 12
- 239000011719 vitamin A Substances 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 6
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 6
- 229940067631 phospholipid Drugs 0.000 claims abstract description 5
- 244000269722 Thea sinensis Species 0.000 claims abstract 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 11
- 229920002670 Fructan Polymers 0.000 claims description 9
- 241001474374 Blennius Species 0.000 claims description 5
- 235000014375 Curcuma Nutrition 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 29
- 235000013601 eggs Nutrition 0.000 abstract description 28
- 230000035764 nutrition Effects 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004556 brain Anatomy 0.000 abstract description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 11
- 239000013589 supplement Substances 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 235000021152 breakfast Nutrition 0.000 abstract description 3
- 230000037406 food intake Effects 0.000 abstract description 3
- 235000012631 food intake Nutrition 0.000 abstract description 3
- 235000021486 meal replacement product Nutrition 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 19
- 235000012000 cholesterol Nutrition 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 102000002322 Egg Proteins Human genes 0.000 description 9
- 108010000912 Egg Proteins Proteins 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 235000001465 calcium Nutrition 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 235000013345 egg yolk Nutrition 0.000 description 6
- 210000002969 egg yolk Anatomy 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 150000004666 short chain fatty acids Chemical class 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004958 brain cell Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 235000014786 phosphorus Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000446 fuel Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 108010011619 6-Phytase Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000005686 eating Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229940085127 phytase Drugs 0.000 description 3
- 235000020095 red wine Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010018276 Gingival bleeding Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 101150076104 EAT2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001139947 Mida Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- -1 and in short Proteins 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 201000007235 gluten allergy Diseases 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2240/00—Use or particular additives or ingredients
- A23C2240/15—Use of plant extracts, including purified and isolated derivatives thereof, as ingredient in dairy products
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种营养丰富的早茶,该早茶包括鸡蛋粉、脱脂奶粉、姜黄、DHA、白藜芦醇、a‑硫辛酸、菊粉、低聚半乳糖、磷脂、维生素A、维生素C、维生素D、维生素E。本发明一种营养丰富的早茶可以作为代餐产品,本申请的早茶配方营养多样,集保健、食疗、一些疾病的预防作用于一体,可以科学地补充人体所必需的多种营养成分,根据国人的食品摄入的现状,具有为:身体细胞、大脑、肠道、血液及血管提供每天所需营养,使细胞、大脑、肠道、血液及血管保持健康,功能正常运行。
Description
技术领域
本发明涉及营养食品领域,尤其是一种营养丰富的早茶。
背景技术
目前,市场上奶粉及代餐食品的营养多样性欠缺,随着人们生活水平不断提高,对追求健康,保健养生,产品的需要,日见强烈,对摄入的食物价值,吃对食物的要求越来越高,一款具有:保健养生,营养均衡,疾病预防控制,食疗效果的产品尤为重要。因此,需要设计一种营养丰富的早茶。
发明内容
为了克服现有技术中的缺陷,提供一种营养丰富的早茶。
本发明通过下述方案实现:
一种营养丰富的早茶,该早茶包括鸡蛋粉、、脱脂奶粉、姜黄、DHA、白藜芦醇、a-硫辛酸、菊粉、低聚半乳糖、磷脂、维生素A、维生素C、维生素D、维生素E。
该早茶按照每袋33克计算,每袋早茶中含有以下含量的成分:
鸡蛋粉:11g-11.5g;
脱脂奶粉:14.g-14.5g;
姜黄:260mg-300mg;
DHA:650mg-700mg;
白藜芦醇:100mg-110mg;
a-硫辛酸:220mg-230mg;
菊粉:3.5g-4g;
低聚半乳糖:0.66g-0.99g;
磷脂:0.33g-0.66g;
维生素A:130ugRE-140ugRE;
维生素C:9mg-11mg;
维生素D:1.8ug-2.0ug;
维生素E:2.6mga-TE-2.8mga-TE。
所述DHA从海藻中提取。
所述菊粉中含有长链菊粉型果聚糖和短链菊粉型果聚糖。
本发明的有益效果为:
本发明一种营养丰富的早茶可以作为代餐产品,本申请的早茶配方营养多样,集保健、食疗、一些疾病的预防作用于一体,可以科学地补充人体所必需的多种营养成分,根据国人的食品摄入的现状,具有为:身体细胞、大脑、肠道、血液及血管提供每天所需营养,使细胞、大脑、肠道、血液及血管保持健康,功能正常运行。
具体实施方式
下面对本发明优选的实施例进一步说明:
一种营养丰富的早茶,该早茶包括鸡蛋粉、、脱脂奶粉、姜黄、DHA、白藜芦醇、a-硫辛酸、菊粉、低聚半乳糖、磷脂、维生素A、维生素C、维生素D、维生素E。
该早茶按照每袋33克计算,每袋早茶中含有以下含量的成分:
鸡蛋粉:11g-11.5g;
脱脂奶粉:14.g-14.5g;
姜黄:260mg-300mg;
DHA:650mg-700mg;
白藜芦醇:100mg-110mg;
a-硫辛酸:220mg-230mg;
菊粉:3.5g-4g;
低聚半乳糖:0.66g-0.99g;
磷脂:0.33g-0.66g;
维生素A:130ugRE-140ugRE;
维生素C:9mg-11mg;
维生素D:1.8ug-2.0ug;
维生素E:2.6mga-TE-2.8mga-TE。
所述DHA从海藻中提取。
所述菊粉中含有长链菊粉型果聚糖和短链菊粉型果聚糖。
下面结合具体实施例对本申请的技术做进一步阐述:
实施例1
一种营养丰富的早茶,该早茶包括鸡蛋粉、、脱脂奶粉、姜黄、DHA、白藜芦醇、a-硫辛酸、菊粉、低聚半乳糖、磷脂、维生素A、维生素C、维生素D、维生素E。
该早茶按照每袋33克计算,每袋早茶中含有以下含量的成分:
鸡蛋粉:11gg;
脱脂奶粉:14.5g;
姜黄:280mg;
DHA:650mg;
白藜芦醇:110mg;
a-硫辛酸:225mg;
菊粉:3.5g;
低聚半乳糖:-0.99g;
磷脂:0.44g;
维生素A:130ugRE;
维生素C:11mg;
维生素D:1.9ug;
维生素E:2.7mga-TE。
所述DHA从海藻中提取。
所述菊粉中含有长链菊粉型果聚糖和短链菊粉型果聚糖。
实施例2
本实施例中与实施例1相同之处不再赘述,不同之处如下所述:
该早茶按照每袋33克计算,每袋早茶中含有以下含量的成分:
鸡蛋粉:11.2g;
脱脂奶粉:14.g;
姜黄:300mg;
DHA:680mg;
白藜芦醇:100mg;
a-硫辛酸:230mg;
菊粉:3.7g;
低聚半乳糖:0.66g;
磷脂:0.66g;
维生素A:135ugRE;
维生素C:9mg;
维生素D:2.0ug;
维生素E:2.7mga-TE。
实施例3
本实施例中与实施例1相同之处不再赘述,不同之处如下所述:
该早茶按照每袋33克计算,每袋早茶中含有以下含量的成分:
鸡蛋粉:11.5g;
脱脂奶粉:14.2g;
姜黄:260mg;
DHA:700mg;
白藜芦醇:105mg;
a-硫辛酸:220mg;
菊粉:4g;
低聚半乳糖:0.77g;
磷脂:0.33g;
维生素A:140ugRE;
维生素C:10mg;
维生素D:1.8ug;
维生素E:2.8mga-TE。
下面结合本申请中各个成分的功效对本发明做进一步解读:
脱脂奶粉的功效与作用:1.脱脂奶粉是将鲜牛奶脱去脂肪再干燥而成,将脂肪降低至1%左右,其他营养成分无变化。2.能增强免疫力,脱脂奶粉中的血蛋白,乳蛋白,乳清蛋白比较丰富,能满足人体所需的微量元素提高人体的免疫能力,并对于各种肿瘤和心血管疾病有很好的预防和印制功效。
鸡蛋粉的功效与作用:1.鸡蛋粉是以鲜鸡蛋为原料加工而成的一种粉末,它具有:补血活血,滋阴润燥,养心安神的功效,经常吃鸡蛋粉,可以有效的吸收其中的DHA,从而改善记忆力,营养脑神经,对失眠多梦,记忆力减退,老年痴呆等现象有很好的辅助治疗作用,鸡蛋的营养成分很全面,富含优质蛋白,钙,磷,硫,铁等营养元素,能促进脑细胞的繁殖,提高记忆力,健脑益智,促进骨骼生长,预防骨质疏松,能降低血清胆固醇及血黏度,软化血管,促进血液循环,预防心血管疾病等,延缓皮肤衰老,预防老年斑及雀斑的形成。2.鸡蛋主要价值,据分析,每百克鸡蛋含蛋白质12.58克,主要为卵白蛋白和卵球蛋白,其中含有人体必需的8种氨基酸,并与人体蛋白的组成极为近似,人体对鸡蛋蛋白质的吸收率可高达98%,每百克鸡蛋含脂肪11-15克,主要集中在蛋黄里,也极易被人体消化吸收,蛋黄中含有丰富的卵磷脂,固醇类,蛋黄素以及钙,磷,铁,维生素A,维生素D及B族维生素。3.一个鸡蛋所含热量,相当于半个苹果或半杯牛奶的热量,它还拥有人体每天所需8%的磷,4%的锌,4%的铁,12.58%的蛋白质,3%的维生素E,6%的维生素D,6%维生素A,2%的维生素B6,这些营养都是人体必不可少的,它们起着及其重要的作用,修复人体组织,形成新的组织,消耗能量和参与复杂的新成代谢过程等。4.特别说明其中胆固醇,鸡蛋黄中含有较多胆固醇,百克可高达510毫克,因此,不少人,特别是老年人对吃鸡蛋怀有戒心,怕吃鸡蛋引起胆固醇增高而导致动脉粥样硬化,卵磷脂进入血液后会使胆固醇和脂肪的颗粒变小,并使之保持悬浮状态,从而阻止胆固醇和脂肪在血管壁的沉积,因此,科学家们认为,对胆固醇正常的老年人,每天吃2个鸡蛋,其100毫升血液中的胆固醇最高增加2毫克,不会造成血管硬化。5.鸡蛋中蛋氨酸含量特别丰富,而谷类和豆类都缺乏这种人体必需的氨基酸,鸡蛋还有其它微营养素,如钾,钠,镁,特别是蛋黄中的铁达7毫克/100克,蛋中的磷很丰富,但钙相对不足,所以,将奶类与鸡蛋共同食用可营养互补。
姜黄的功效与作用:1.姜黄是姜科植物的一种,中国古典中也明确记载姜黄的功效《唐本草》记载“主心腹结积,疰忤,下气,破血,除风热,消广痈肿,功力强于郁金”。新世纪姜黄也用于更广泛的用途。解酒护肝成为姜黄最具实用性的效用,姜黄中所含的姜黄醇,姜黄素和挥发油都有明矿显的降血浆总胆固醇,肝胆固醇及一脂蛋白的作用,姜黄素能降低肝重,减少肝中各种脂类含量,抑制脂肪酸的合成。姜黄的抗炎症和抗氧化作用早已被人们所熟知,目前有科学家正在积极研究它在神经病学中的应用,特别是流行病学家们,他们正在寻找解释痴呆症在大量使用姜黄粉的群体中显著降低的线索。3.新的研究表明,姜黄能够促进新的脑细胞生长,有一些科学家看来,姜黄甚至可以媲美氟西汀的抗抑郁作用。4.在中国和印度医学中,姜黄已经作为治疗各种疾病的天然药物使用了几千年之久。姜黄素是享姜黄中最具有活性的成分,它可激活基因,产生大量的抗氧化剂,从而保护我们宝贵的线粒体,它还可以改善葡萄糖代谢,这也是维持肠道细菌健康与平衡的好方法。
DHA的功效与作用:最近或许没有哪种刺激大脑的分子像是二十二碳六烯酸(Docosah-exaenoicAcid)--也就是DHA这样备受关注了,在过去的几十年中,科学家们出于3个原因积极地研究这一至关重要的大脑脂肪酸,首先,大脑脱水干重的2/3是脂肪,在这些脂肪中1/4是DHA.从结构上而言,DHA是包围着脑细胞的细胞膜,特别是作为大脑有效的功能核心的突触的重要构成要素。其次,DHA是一种炎症的重要调节成分。它能够自然地降低环氧化酶-2的活性。而环氧化酶-2正是启动有害的炎症化学物质产生的关键一环,当吃进不卫生的食物的时候,DHA还会在敌人领地中以多种方式像斗士一样与敌人对抗。对于麸质过敏的人,它能够在肠道内壁的战斗中还击炎症。而且,它能够阻止高糖分饮食(特别是果糖)的破坏作用,有助于防止饮食中过多的碳水化合物造成的大脑代谢性障碍。再次,可以说DHA最令人兴奋的活动是它在调节产生脑源性神经营养因子的基因表达中的作用,简单来说,DHA有助于协调安排大脑细胞的产生,连接和生存,并同时增强功能。在2014年完成的一项首字母缩写为MIDAS(Memory lmprovement with DHA study)的双盲干预性实验中,参与的人群485名有轻度记忆力问题的老年人,其平均年龄为70岁。研究人员给他们一种含有从海藻中提取的DHA的胶囊或者安慰剂,服用6个月,在研究结束时,服用DHA的组不仅血液中的DHA翻了一倍,而且对大脑功能的作用也十分显著,这项研究的首席研究人员卡林.尤尔科-莫罗(Karin yurko-Mauro)博士评论道,“在我们的研究中,与服用安慰剂的组相比,有记忆问题的健康人服用海藻DHA胶囊6个月后,在学习和记忆能力测试中错误减少的情况翻了一倍…其益处大约相当于年轻3岁的人的学习和记忆能力。”另一项有815名65-94岁的老年人参加的研究发现,摄入DHA最多的那些人患阿尔兹海默症的风险令人吃惊地降低了60%,这一保护程度优于其他流行的脂肪酸,比如EPA和亚油酸,氟雷明汉心脏研究也指出了其非凡的保护效果,研究人员将899名参与者在近10年血液中DHA的水平进行了比较,在这期间有些人患上痴呆症,他们计算出保持血液中DHA水平高的那些人经诊断患上这种疾病的风险要低47%。
我们如何提高我们体内DHA水平呢?我们能够用日常膳食中的一种欧米伽-3脂肪酸(即a-亚油酸),合成DHA,但是从食物中得到全部所需的DHA很困难,而且我们也无法依赖身体自然产生的DHA,每日我们需要至少200-300毫克DHA.然而大多数中国人消耗的DHA不到目标量的1/5.而且应该摄入超过最低限量的DHA.
人体会产生一系列令人惊叹的酶,人体正常代谢过程中在体内产生毒素以及外部环境接触到的毒素都由这些酶来解毒,这些酶的产生听命于DHA,已经经历了数百万年的进化。
白藜芦醇的功效与作用:1.每天喝一杯红酒对健康有益的秘密与这种在葡萄中发现的天然化合物息息相关,这种成分不仅减缓衰老的过程,提高大脑的血流量,还能促进心脏健康,它还被证明能够通过控制脂肪细胞的发展来抑制脂肪细胞,不过,你无法从一杯红酒中获得足够的白藜芦醇,因此需要更高剂量的补充才能使人从中获益。2.由于这种所谓的奇迹分子能保护细胞免受许多种类疾病之苦,所以它常被标榜为人体免疫和防御系统的帮手,在过去的十几年中,我们认识到了这是如何实现的,这在很大程度上要感谢哈弗大学的戴维.辛克莱(David Sinclair)博士的工作,他发现了这种补剂有激活影响长寿的叫作去乙酰化酶的特定基因的能力。2010年,因国的诺森比亚大学(Northum bria University)的科学家在美国临床营养期刊(American Journal of Clinical Nutrition)上发表了一项研究报告,讨论到底为什么白藜芦醇可以有效地优化大脑功能。他们在研究报告中说他们让24名学生服用白藜芦醇,然后再让这些学生做智力测试时,他们记录到这些学生大脑的血流量出现显著的增加。测试难度越高,白藜芦醇的影响就越显著。3.我们知道每天额外摄入温和剂量的白藜芦醇对大脑有好处,注意是温和剂量,虽然之前科学暗示要从中获益需要非常大的剂量(相当于喝数百瓶红酒中剂量),较新的研究明确地表示较低剂量(每天4.9毫克)即可产生积极作用。
a-硫辛酸的功效与作用:这种脂肪酸存在于身体的每一个细胞之中,细胞需要a-硫辛酸生产身体正常功能所需的能量,它跨越血脑屏障,在大脑的水样和脂肪两种组织中都是一种强大的抗氧化物质,科学家现在正在研究将a-硫辛酸作为一种潜在治疗中风和其他与自由基损害有关的脑部疾病,比如痴呆症。虽然身体能够产生足够量的这种脂肪酸,但是服用补剂对我们的现在生活方式和不当的饮食有益。
菊粉的功效与作用:1.控制血脂,合理摄入菊粉可以有效降低血清胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C).提高高密度脂蛋白/低密度脂蛋白比率,改善血脂状况,Hidaka等人报道,50-90的老年病人,每日摄入8g短链的膳食纤维,两周后血液中甘油三酸酯和总胆固醇的水平降低,。Yamashita等人给18名糖尿病人进食8g菊粉两周,总胆固醇减少7.9%.胆HDL-胆固醇没变,Brighenti等人观察到,12名健康年轻男子,在每日的谷物早餐中加入9g菊粉共4周,总胆固醇减少8.2%,甘油三酯酸酯则大幅降低26.5%。许多膳食纤维通过吸收肠内脂肪,形成脂肪--纤维复合物随粪便排出,从而降低血脂水平,而且,菊粉在肠道末端前,自身就发酵成短链脂肪酸和乳酸盐,乳酸盐是肝脏代谢的调节剂。短链脂肪酸(醋酸盐和丙酸盐)在血液里可作燃料,丙酸盐抑制胆固醇的合成。
2.降低血糖,菊粉是一种不会导致尿中葡萄糖升高的碳水化合物。它在肠道的上部不会被水解成单糖,因而不会升高糖水平和胰岛素含量,如今研究表明.空腹血糖的降低是低聚果糖在结肠发酵所产生的短链脂肪酸的结果。
3.促进矿物质的吸收,菊粉能大大提高Ca2+.Mg2+.Zn2+.CU2+.Fe2+等矿物质的吸收。据报道,青少年食用8g/d(长和短链菊粉型果聚糖)分别8周和1年,结果发现,都显著提高Ca2+吸收,而且身体的骨骼矿物质含量和密度也显著增加。菊粉促进矿物质元素吸收的主要机制是:1)菊粉在结肠发酵生产的短链脂肪使其黏膜上的隐窝变浅,隐窝细胞增多从而增大了吸收面积,盲肠静脉更发达。2)发酵所产生的酸降低结肠PH质,使得许多矿物质的溶解度,生物有效性得以提高,特别是短链脂肪酸可以刺激结肠粘膜细胞生长,提高肠黏膜的吸收能力。3)菊粉能促进一些微生物分泌植酸酶,植酸酶能使与植酸螯合的金属离子释放出来,促进其吸收。4)发酵生成分某些有机酸可与金属离子螯合,促进金属离子吸收。
4.调节肠道微生物菌群,改善肠道健康,防止便秘,菊粉是一种天然的水溶性膳食纤维,几乎不能被胃酸水解和消化,只有在结肠被有益生物利用,从而改善肠道环境,有研究表明,双歧杆菌的增殖程度取决于人体大肠中初始双歧杆菌的数量,当初始双歧杆菌减少时使用菊粉后效果并不明显,其次,摄入菊粉后能增强胃肠道蠕动,提高胃肠道功能,增加消化和食欲,提高机体免疫力。
5.抑制有毒发酵物的生产,保护肝脏,预防结肠癌,食物经消化吸收后到达结肠,在肠道腐生菌(大肠杆菌、拟杆菌等)的作用下,可产生许多有毒的代谢产物(如氨,亚硝胺,苯酚与甲苯酚、次级胆汁酸等),而菊粉在结肠被发酵生产的短链脂肪酸能够降低结肠PH质,抑制腐生菌的生长,减少有毒产物的生成,减少对肠壁的刺激,由于菊粉一系列代谢活动能抑制有毒物质产生,增加排便次数,增加粪便酸度,加速致癌物的排泄,产生有抗癌作用的短链脂肪酸,有利于预防结肠癌。
6.防便秘及治疗肥胖症膳食纤维减少食物在胃肠道的停留时间,以及增加粪便量,有效地治疗便秘。其减肥作用是提高内容物的黏度,降低食物从胃进入小肠的速度,从而降低饥饿感,减少食物的摄入量。
7.菊粉中有少量的2-9低聚果糖,研究表明,低聚果糖可使大脑神经细胞营养因子表达升高,对皮质酮诱导的神经元有很好的保护作用,具有良好的抗抑郁作用。
低聚半乳糖的功效与作用:低聚半乳糖(GalactooligoSaccharides.GOS)是一种具有天然属性的功能性低聚糖,在三种低聚糖中,低聚半乳糖是唯一都能够被人体肠内8大有益菌所利用的,是肠道中的双歧杆菌,嗜酸乳酸杆菌,干酪乳杆菌,唾液乳杆菌,有益菌极好的营养源和有效的,增殖因子,可以改善人体肠道的消化吸收功能。
磷脂的功效与作用:1.人体所需的外源性胆碱90%是由磷脂提供。2.健康心脏,大脑,脑细胞中卵磷脂的含量约占其质量的17-20%.“胆碱”是大豆卵磷脂成分,卵磷脂充分供应保证“胆碱”与人体内的“乙酰”合成为“乙酰胆物质,从而提高脑细胞的活性化程度。3.有调节血清脂质水平意味着能降低胆固醇水平,保护肝脏,也能改善记忆力,加强免疫力以及抗脂肪肝的活力等等。
维生素A的功效和作用:1、防治夜盲症和视力减退,有助于多种眼疾的治疗;
2、有抗呼吸系统感染作用;
3、有助于免疫系统功能正常;
4、生病时能早日康复;
5、能保持组织或器官表层的健康;
6、有助于祛除老年斑;
7、促进发育,强壮骨骼,维护皮肤、头发、牙齿、牙龈的健康;
8、有助于对肺气肿、甲状腺机能亢进的治疗。
维生素C的功效和作用:
1、促进骨胶原的生物合成,利于组织创伤口的更快愈合。
2、促进氨基酸中酪氨酸和色氨酸的代谢,延长肌体寿命。
3、改善铁、钙和叶酸的利用;改善脂肪和类脂特别是胆固醇的代谢,预防心血管疾病。
4、促进牙齿和骨骼的生长,防止牙床出血,防止关节痛、腰腿痛。
5、增强肌体对外界环境的抗应激能力和免疫力。
6、水溶性强抗氧化剂,主要作用在体内水溶液中。
7、坚固结缔组织;促进胶原蛋白的合成,防止牙龈出血。
维生素D的功效和作用:
1、维持血液钙和磷稳定,包括促进钙吸收和骨吸收。
2、参与某些蛋白质转录的调节,维生素D的这种特性可以解释其在骨吸收、肠腔内钙转运以及皮肤中的作用。
3、参与体内免疫调节。
维生素E的功效和作用:
1、延缓衰老,有效减少皱纹的产生,保持青春的容貌。
2、减少细胞耗氧量,使人更有耐久力,有助减轻腿抽筋和手足僵硬的状况。
3、抗氧化保护机体细胞免受自由基的毒害。
4、改善脂质代谢,预防冠心病、动脉粥样硬化。后来2000年新英格兰医学杂志上就有文章用超过9000人的严格随机实验证明维生素E根本不能降低冠心病风险,这一结论从此之后再也没被推翻过。
5、预防癌症,有效抑制肿瘤生长;预防多处慢性疾病;预防炎症性皮肤病、脱发症;预防溶血性贫血、保护红血球使之不容易破裂;预防治疗甲状腺疾病;改善血液循环、保护组织、降低胆固醇、预防高血压。
6、强化肝细胞膜、保护肺泡细胞,降低肺部及呼吸系统遭受感染的几率。
7、保护皮肤免受紫外线和污染的伤害,减少疤痕与色素的沉积;加速伤口的愈合。
8、促进性激素分泌,使男子精子活力和数量增加;使女子雌性激素浓度增高,提高生育能力,预防流产。
本申请的早茶是对人体营养健康最有价值的代餐产品,改变摄入营养单一性,适合中国人现代饮食习惯的体质,使其合理均值摄入每天所需营养的全面性。具有食疗、保健养生、对一些疾病预防作用。
3岁至18岁人群每天早上饮用一袋本申请的一种营养丰富的早茶(33g),可以补充一天的多样性营养,促进骨骼生长,大脑发育,保护肠道,益生菌殖生,降低坏的微生物生长,保护细胞,降低炎症因子提供身体细胞燃料。
成年人早上饮用一袋本申请的一种营养丰富的早茶(33g),补充一天的多样性营养,给身体提供营养,给大脑提供营养,保护大脑,提高工作效率,保护肠道给有益菌提供燃料,使其殖生,防止坏微生物生长,保护心脑血管,避免脂肪堆积,保护肝脏,为细胞提供营养,降低炎症因子,增强免疫功能,配合每天25分钟的锻炼,避免亚健康。
中老年人每天早上饮用一袋本申请的一种营养丰富的早茶(33g),补充一天的多样性营养成分。为大脑提供营养,保护大脑降低炎症因子避免退行性疾病比如老年痴呆症,心脑血管病,延缓衰老,增强免疫功能。保护肠道,给有益菌提供燃料,使其殖生,防止坏的微生物生长,防止肠道渗漏。
本申请的一种营养丰富的早茶为早上忙碌的,上班族,学生,提供一天的营养多样性一定保障,为出差人士方便携带,保障出差的每一天的多样性营养,为养生人士提供每天所需营养的多样性,使其长期保持良好的健康状态。
尽管已经对本发明的技术方案做了较为详细的阐述和列举,应当理解,对于本领域技术人员来说,对上述实施例做出修改或者采用等同的替代方案,这对本领域的技术人员而言是显而易见,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (4)
1.一种营养丰富的早茶,其特征在于:该早茶包括鸡蛋粉、、脱脂奶粉、姜黄、DHA、白藜芦醇、a-硫辛酸、菊粉、低聚半乳糖、磷脂、维生素A、维生素C、维生素D、维生素E。
2.根据权利要求1所述的一种营养丰富的早茶,其特征在于,该早茶按照每袋33克计算,每袋早茶中含有以下含量的成分:
鸡蛋粉:11g-11.5g;
脱脂奶粉:14.g-14.5g;
姜黄:260mg-300mg;
DHA:650mg-700mg;
白藜芦醇:100mg-110mg;
a-硫辛酸:220mg-230mg;
菊粉:3.5g-4g;
低聚半乳糖:0.66g-0.99g;
磷脂:0.33g-0.66g;
维生素A:130ugRE-140ugRE;
维生素C:9mg-11mg;
维生素D:1.8ug-2.0ug;
维生素E:2.6mga-TE-2.8mga-TE。
3.根据权利要求1所述的一种营养丰富的早茶,其特征在于:所述DHA从海藻中提取。
4.根据权利要求1所述的一种营养丰富的早茶,其特征在于:所述菊粉中含有长链菊粉型果聚糖和短链菊粉型果聚糖。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110780131.6A CN113508841A (zh) | 2021-07-09 | 2021-07-09 | 一种营养丰富的早茶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110780131.6A CN113508841A (zh) | 2021-07-09 | 2021-07-09 | 一种营养丰富的早茶 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113508841A true CN113508841A (zh) | 2021-10-19 |
Family
ID=78067193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110780131.6A Pending CN113508841A (zh) | 2021-07-09 | 2021-07-09 | 一种营养丰富的早茶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113508841A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105394182A (zh) * | 2015-10-27 | 2016-03-16 | 江西美庐乳业集团有限公司 | 一种具有降血糖功效及促进心脑血管健康的营养包 |
CN106135797A (zh) * | 2015-04-27 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | 一种有助于调节血糖的营养组合物及其制备方法 |
CN106616998A (zh) * | 2016-12-30 | 2017-05-10 | 北京康比特体育科技股份有限公司 | 一种营养代餐的组合物及其应用 |
CN109998118A (zh) * | 2019-05-10 | 2019-07-12 | 雷件文 | 一种功能性营养早餐谷物食品 |
-
2021
- 2021-07-09 CN CN202110780131.6A patent/CN113508841A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106135797A (zh) * | 2015-04-27 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | 一种有助于调节血糖的营养组合物及其制备方法 |
CN105394182A (zh) * | 2015-10-27 | 2016-03-16 | 江西美庐乳业集团有限公司 | 一种具有降血糖功效及促进心脑血管健康的营养包 |
CN106616998A (zh) * | 2016-12-30 | 2017-05-10 | 北京康比特体育科技股份有限公司 | 一种营养代餐的组合物及其应用 |
CN109998118A (zh) * | 2019-05-10 | 2019-07-12 | 雷件文 | 一种功能性营养早餐谷物食品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5497634B2 (ja) | 術前及び/又は術後環境におけるプロバイオティックス | |
CN101223999B (zh) | 一种全面补充各种人体所需的营养素组合物 | |
CN106072573A (zh) | 一种适用于老年肌肉衰减症食用的特膳食品 | |
CN111616232A (zh) | 一种促进骨骼生长的儿童奶粉及其制备方法 | |
WO2022016774A1 (zh) | 利于调节肠道、促进消化、改善便秘的组合物及其制备方法 | |
CN103238897A (zh) | 一种适用于糖尿病人的复合植物固体饮料 | |
WO2005023021A1 (ja) | ダイエット食品 | |
US20230132388A9 (en) | Intact Pea Protein-Based Nutrient Composition | |
PT2100604E (pt) | Ácidos dicarboxílicos de cadeia média e os seus derivados e doenças metabólicas | |
CN111990463A (zh) | 一种牛初乳复合粉 | |
CN109430407A (zh) | 益生菌组合制剂 | |
CN110226744A (zh) | 一种前列腺炎专用型临床营养配方及其制备方法 | |
CN108077911A (zh) | 一种癫痫患者专用型临床营养配方及其制备方法 | |
CN104605353A (zh) | 适用于手术后肿瘤患者食用的配方食品及其制备方法 | |
CN110432482A (zh) | 一种小儿过敏性皮炎专用型临床营养配方及其制备方法 | |
CN108391811A (zh) | 一种肿瘤全营养配方食品及其应用 | |
CN103190483A (zh) | 儿童成长奶茶 | |
CN112352955A (zh) | 一种基于生酮原理干预多囊卵巢综合症的低gi全营养代餐粉及其应用 | |
CN111543605A (zh) | 一种四高或肥胖人群用综合营养粉 | |
CN110710660A (zh) | 含有苦瓜粉的降低血糖组合物及膳食补充剂 | |
CN112385843A (zh) | 含复合益生元的均衡营养粉及其制备方法 | |
CN110214942A (zh) | 一种甲亢专用型医学营养配方及其制备方法 | |
CN108541912A (zh) | 一种抗氧化降血脂组合物及其制备方法和应用 | |
CN112189839A (zh) | 一种辅助降血脂组合物及其应用 | |
CN110584120A (zh) | 骨健康组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211019 |